Metformin

Generic Name: Metformin

Brand Names: Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₁N_₅

CAS Number: 657-24-9

Unique Ingredient Identifier: 9100L32L2N

Background: Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.

Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.

Indication: Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)

The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.

Metformin combination products

Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate

Associated Therapies: -

Clinical Trials

Preventing Injured Knees From osteoArthritis: Severity Outcomes

Phase 2

Recruiting

Conditions: ACL Tear
Osteoarthritis, Knee
Post-traumatic Osteoarthritis

Interventions: Drug: Placebo
Drug: Metformin

First Posted Date: 2023-10-23

Last Posted Date: 2024-05-09

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 512

Registration Number: NCT06096259

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
Hospital for Special Surgery, New York, New York, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 6 locations

Effect of Life Style Modification and Metformin on Hypothyroidism With Insulin Resistance

Phase 4

Not yet recruiting

Conditions: Hypothyroidism
Insulin Resistance

Interventions: Drug: Metformin

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Assiut University

Target Recruit Count: 100

Registration Number: NCT06096454

Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.

Phase 1

Not yet recruiting

Conditions: Alopecia Areata

Interventions: Drug: Betamethasone Valerate 0.1% Cream
Drug: Pentoxifylline
Drug: Metformin

First Posted Date: 2023-10-18

Last Posted Date: 2023-10-18

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT06087796

Locations: 🇪🇬
Assiut university, Assiut, Egypt

Evaluation of the Effects of Diosmin/Hespiridin Combination on the Clinical Outcomes in Patients With Polycystic Ovary Syndrome

Phase 4

Not yet recruiting

Conditions: Poly Cystic Ovary Syndrome

Interventions: Drug: Daflon
Drug: Combined oral contraceptive
Drug: Metformin

First Posted Date: 2023-10-16

Last Posted Date: 2023-10-16

Lead Sponsor: Ain Shams University

Target Recruit Count: 120

Registration Number: NCT06083935

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Phase 3

Withdrawn

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Metformin
Drug: Empagliflozin

First Posted Date: 2023-10-16

Last Posted Date: 2024-02-26

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT06083675

Locations: 🇹🇭
Songklanagarind Hospital, Songkla, Thailand
🇬🇷
General Hospital of Thessaloniki "G.Papanikolaou", Thessaloniki, Greece
🇵🇱
ETG Siedlce, Siedlce, Masovian, Poland

and more 97 locations